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Abstract 
 
Common variable immunodeficiency (CVID), the most common symptomatic primary 
antibody deficiency, is accompanied in some patients by a duodenal inflammation and 
malabsorption syndrome known as CVID enteropathy (E -CVID).  The goal of this study 
was to investigate the immunological abnormalities in CVID patients that lead to 
enteropathy as well as the contribution of intestinal microbiota to this process.  We 
found that, in contrast to noE-CVID patients (without enteropathy), E-CVID patients 
have exceedingly low levels of IgA in duodenal tissues. In addition, using transkingdom 
network analysis of the duodenal microbiome, we identified Acinetobacter baumannii as 
a candidate pathobiont in E-CVID. Finally, we found that E-CVID patients exhibit a 
pronounced activation of immune genes and down-regulation of epithelial lipid 
metabolism genes. We conclude that in the virtual absence of mucosal IgA, pathobionts 
such as A. baumannii, may induce inflammation that re-directs intestinal molecular 
pathways from lipid metabolism to immune processes responsible for enteropathy. 
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Introduction 
 
Common variable immunodeficiency (CVID), the most frequently occurring form of 
symptomatic immunodeficiency, is a heterogeneous disease that is most likely due to  
many different genetic defects [1-4]. With the advent of early gamma globulin 
replacement therapy, CVID patients are relatively free from life-threatening infections 
and have a more prolonged survival [1, 3, 5]. The latter, however, has revealed that 
CVID can be associated with other problems not due to infectious agents.  One of 
these, CVID enteropathy, is characterized by villous atrophy, malabsorption and 
diarrhea and occurs in up to 15% of CVID patients in symptomatic form and perhaps in 
a larger percentage in enteropathy since this manifestation of the disease has not been 
coupled to a particular asymptomatic form [6],[7]. No genetic differences accounting for 
the hypogammaglobulinemia in the subset of patients that develop enteropathy and 
those that do not have been identified in prior studies or in the present study (see 
below); thus, a genetic basis for the occurrence of enteropathy is not yet known. 
The villous atrophy accompanying CVID enteropathy is histologically similar to that in 
celiac disease and, as such, is characterized by a lamina propria mononuclear cell 
infiltration and increased numbers of intra-epithelial lymphocytes; however, the 
prominent plasma cell infi ltration seen in celiac disease is not present [7]. Studies 
conducted by Malamut et al. [7], showed that intraepithelial lymphocytes (IELs) in celiac 
disease differed from those in CVID enteropathy with regard to  some natural killer cell 
markers and the TCR/ phenotype characteristic of that in celiac disease was generally 
not present in CVID. These differences between CVID and celiac disease were 
corroborated by recent work showing that the two diseases are also quite distinct in 
gene profi ling studies [8].  Finally, studies of the immunologic features of CVID 
enteropathy conducted by Mannon et al.[9] revealed that lamina propria T cells 
extracted from patients with this disease produce increased amounts of IL-12 and IFN- 
but little if any IL-17.  These findings correlate with recent studies showing that 
increased numbers of innate (CD3
-
) ILC3 cells producing IFN- are present in mucosal 
tissues of patients with CVID but not patients with IBD; thus, these cells may also 
contribute to the Th1 cytokine bias associated with enteropathy [10]. 
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In previous work we have shown using systems biology methodology that total 
immunoglobulin and IgA deficiency in mice are associated with a remarkable up-
regulation of gut epithelial interferon-inducible genes accompanied by a down-regulation 
of GATA4-related metabolic genes [11].  Since these changes were not seen in germ-
free mice it was clear that they were dependent on one or more organisms in the gut 
microbiota. These studies therefore suggested that CVID enteropathy may be 
characterized by the presence of an immune defect that leads to colonization with an 
organism that is responsible for these multiple gene expression changes. To address 
this possibility we conducted immunologic studies of CVID patients with and without 
enteropathy as well as control individuals and found that patients with enteropathy but 
not those without enteropathy exhibited the interferon gene/metabolic gene imbalance 
mentioned above.  In addition, patients with CVID enteropathy could be distinguished 
from those without enteropathy by the presence of vanishingly low mucosal IgA levels, 
irrespective of accompanying serum IgA levels. We then used these immunologic data 
and accompanying microbiome data to conduct a systems biology and transkingdom 
network analysis [12] for the identification of a possible candidate bacterium capable of 
causing villous atrophy and malabsorption in the absence of mucosal IgA secretion.  
 
Results 
 
General clinical immunological and genetic characteristics of the patients under 
study 
 
The patient/control groups studied here consisted of biopsies of 7 patients with E-CVID, 
8 patients with noE-CVID and 7 control individuals; the relevant patient clinical history, 
histopathologic information accompanying these patient/control groups are provided in 
the Methods section. All patients underwent peripheral blood B and T cell phenotyping. 
In evaluation of their B cells, E-CVID patients exhibited a decrease in total B cells as 
signified by expression of CD20: mean absolute number CD20+ B cells of 47 cells/uL in 
E-CVID patients as compared with 158 cells/uL in noE-CVID patients with normal 
control patients 111 cells/uL. In addition, E-CVID patients exhibited a decreased 
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number of memory B cells as signified by the number of CD20/CD27+ cells: mean 
absolute number of CD20/CD27+ cells of 11.8 cells/uL in E-CVID patients as compared 
with 17.2 cells/uL in noE-CVID patients with normal control patients 28 cells/uL. This 
apparent difference in memory B cells in E-CVID patient group as compared to noE-
CVID patient group, however, did not reach statistical significance. In evaluation of their 
T cells, no significant differences was observed among E-CVID patients, noE-CVID 
patients and normal controls with respect to absolute number of CD3+ T cells:  mean 
absolute cell number for E-CVID patients: 1150 cells/uL, noE-CVID patients: 1332  
cells/uL and normal control patients: 1268 cells/uL. However, in analysis of T cell 
subsets, E-CVID patients exhibited a decreased CD4+/CD8+ ratio as compared to no-
ECVID patients. This was reflected in the mean absolute cell number of CD4+ T cells of 
463 cells/uL in E-CVID patients as compared to 762 cells/uL in noE-CVID patients and 
CD8+ T cells of 899 cells/uL in E-CVID patients as compared to 529 cells/uL in noE-
CVID patients. This apparent increase of CD8+ T cells in the E-CVID group as 
compared to the noE-CVID group, however, did not reach statistical significance. 
As mentioned in the Introduction, no differences in the presence of genes previously 
associated with CVID with and without enteropathy has yet been reported.  To examine 
this possibility in the present group of patients the latter were screened at the NIH with 
targeted Ion Torrent AmpliSeq methodology (see Methods section) which included 
exome sequencing of genes known to be associated with CVID. These included LRBA, 
PIK3, CTLA-4, NFKB1, NFKB2, PIK3R1, IKZF1 (IKAROS), ICOS, TNFSF12 (TWEAK), 
CD19, TNFRSF7 (CD27), IL-21R, TNFRSF13B (TACI), TNFRSF13C (BAFF-R), and 
TNFSF13 (APRIL). Neither CVID patients with enteropathy (E-CVID patients) nor CVID 
patients without enteropathy (noE-CVID patients) exhibited deleterious mutations in 
these specific genes.   
 
Gene expression signature of CVID enteropathy and its accompanying 
inflammatory and lipid metabolism defects 
 
We started by defining the global gene expression profi les of duodenal biopsy tissues 
obtained from CVID patients with and without enteropathy as well as in control 
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individuals using RNA sequencing (see Methods).  This analysis revealed 2573 genes 
that were differentially expressed among the three groups (Figure 1a and 
Supplementary Table S1). Analyzing these gene expression profiles using pairwise 
comparisons between genes, we then defined gene signatures characteristic of CVID 
with enteropathy (E-CVID; 1802 genes), CVID without enteropathy (noE-CVID; 210 
genes) and a general CVID signature common to both patient groups (all-CVID, 561 
genes) (Figures 1a-b, Supplementary Figure S1). Next, focusing on the gene 
expression signature in the various groups (Figure 1b), we identified the down-regulated 
and up-regulated genes corresponding to various Gene Ontology categories as defined 
in Figure 1c. We found that in the E-CVID group but not in the noE-CVID group, down-
regulated genes consisted of those relating to epithelial cell metabolic functions such as 
lipid metabolism and absorption whereas up-regulated genes related to immune 
responses and lymphocyte activation (Figure 1c, upper and lower panels respectively 
and Supplementary Table S2). Thus, these data expanded our previously reported 
results about differential regulation of immunity and lipid metabolism in humans with 
immunodeficiency in that they established for the first time that this phenomenon is a 
specific feature of CVID enteropathy and is not present in other CVID patients or 
controls.  In addition, the difference in the gene signature in the E-CVID and noE-CVID 
patients was not influenced by the presence of norovirus infection as no statistically 
significant differences in gene expression were found in norovirus-positive patient 
samples relative to the expression in other E-CVID patients. 
 
We next used a gene expression approach to estimate which cells were present in the 
small intestinal infiltrate in patients with E-CVID as compared to patients with noE-CVID 
or controls. This consisted of a gene set enrichment analysis (GSEA) in which we 
determined the array of hematopoietic cell signatures as defined previously in the D-
MAP study (Supplementary Table S3 [13, 14]) that were enriched in the intestinal gene 
pool of E-CVID patients compared to the pools of noE-CVID patients or controls. We 
found that the gene signatures of variety of hematopoietic cells were enriched in the 
intestinal gene pool of the E-CVID patients (Figure 1d), most prominently natural ki ller 
cells, M1 macrophages, neutrophils and CD8+ T effector/memory lymphocytes (Figure 
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1d and Supplementary Figure S2a, S2b).  Furthermore, we observed a trend toward a 
reduced presence for memory B cells, plasma cells, naïve CD8+ and CD4+ cells in 
biopsies from E-CVID patients compared to biopsies from noE-CVID patients or 
controls.  Finally, the results with respect to CD8+ cells were not influenced by the 
presence of norovirus infection. 
 
To validate one of the most important inferences about the infiltrating cells derived from 
the above gene expression analysis, we evaluated levels of CD8+ T cell staining in 
biopsies of tissues obtained from representative patients.  The results confirmed the 
gene expression analysis in showing increased infiltration of CD8+ T cells in biopsies of 
E-CVID patients compared to biopsies of noE-CVID patients (Figure 1f). Interestingly, 
this result is compatible with peripheral (circulating) patient cell lymphophenotyping in 
that E-CVID patients exhibited an increase in the absolute numbers of CD8+ T cells 
compared to noE-CVID patients. However, this association is tentative because the 
increase in peripheral cells was not statistically significant. Taken together, these results 
demonstrate that CVID enteropathy is characterized by a complex Th1/cytotoxic T cell-
related infiltration. 
 
Finally, we used GSEA to demonstrate that among the top “leading edge” genes 
expressed in CD8+ T cells were those encoding IFNG and HLA class II molecules and 
for genes expressed in M1 macrophages there were those encoding several 
chemokines such as CXCL9, CXCL10, CCL19, CCL20, CCL5 as well as transcription 
factor IRF1 (Figure 1e). Since expression of these genes is known to be associated with 
features of an inflammatory process, their expression by CD8+ T cells and 
macrophages in E-CVID tissue suggested that these cells are participating or mediating 
intestinal inflammation (Figure 1f; Supplementary Table S4).  
 
Intestinal IgA levels discriminate CVID patients with and without enteropathy 
 
The trend noted above indicating that E-CVID patients’ gene expression exhibited 
decreased enrichment for memory B cells and plasma cell signatures compared with 
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expression in noE-CVID patients suggested to us that these cells might be more 
depleted in the mucosa of the E-CVID group than in the noE-CVID group despite the 
fact that serum immunoglobulins and IgA levels are similarly low in the two groups 
(Figure 2a). To examine this possibility, we extracted the immunoglobulin transcript 
levels from the total duodenal RNAseq data and found that mRNA levels of both IgA 
subclasses (encoded by the IGHA1 and IGHA2 genes) in the mucosa from E-CVID 
patients were strikingly decreased compared to levels in the mucosa from noE-CVID 
patients and the levels in the latter group were much closer to those in control 
individuals (Figure 2b). Similarly, levels of gene expression of each of the four 
subclasses of IgG were also decreased in the E-CVID mucosa compared to noE-CVID 
mucosa and again levels in noE-CVID were similar to those in controls (Figure 2b). 
Finally, transcript levels of IgM were also low but in this case the error bars were quite 
large and the result was therefore ambiguous. It should be noted that overall copy 
numbers of transcripts coding for IGHA1 was 10 times higher than for IgAH2 and 100 
times higher than for IgG genes across all three groups indicating that IgA overall (and 
IgA1 in particular) is the dominant gut immunoglobulin not only in the control small 
intestine but also in noE-CVID patient small intestine.  
 
To corroborate these mRNA data at the protein level we performed 
immunohistochemistry staining of IgA in tissues from E-CVID patients, noE-CVID 
patients and controls; subsequently, one of us (MQ, a gastrointestinal pathologist) 
evaluated the stained tissues in a blinded fashion.  We found that cells expressing IgA 
were absent in duodenal tissues from 6/7 E-CVID patients and infrequently present (at 
best) in the remaining E-CVID patient. In contrast, cells expressing IgA were present in 
the tissues of all but one noE-CVID patients, albeit with reduced levels of IgA staining 
intensity compared to controls (Figure 2c).  Interstitial IgA was not observed in tissues 
from patients in any group indicating that IgA+ plasma cells were indeed the source of 
the staining. These results thus confirmed the mRNA data showing that E-CVID can be 
differentiated from noE-CVID on the basis of mucosal IgA expression despite similarity 
in circulating IgA levels. Taken together with the mRNA data they open the door to the 
possibility that the absence of IgA in the duodenum of E-CVID patients subject the latter 
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to possible colonization/infection with organisms that induce inflammatory T cell and 
macrophage responses that result in villous atrophy.  
 
The Bacterial Microbiome in the CVID Duodenum  
 
We next turned our attention to studies characterizing the bacterial microbiome 
associated with duodenal tissue in CVID.  Recognizing that duodenal tissues contain an 
overwhelming number of human cells compared to microbial cells, we first used a 
targeted gene approach in which bacterial genes were identified by sequencing 16S 
ribosomal RNA genes present in bacterial but not in mammalian genomes. Despite 
previous reports of bacterial overgrowth in fecal material of CVID patients [15], we did 
not observe significant differences in bacterial abundance in duodenal biopsies from the 
E-CVID, noE-CVID and control groups (Supplementary Figure S3). Tissues from each 
of these groups contained bacterial taxa dominated by members of the Proteobacteria, 
Firmicutes, and Actinobacteria phyla and expressing abundant bacteria in the 
Gammaproteobacteria and Bacilli classes (Figure 3a; Supplementary Table S5). 
Importantly, there were not significant differences between the groups in respect to 
overall composition as illustrated by PCoA (Figure 3b) or global diversity evaluated by 
the Shannon index (Figure 3c). Thus, while comparison of abundance of Operational 
Taxonomic Units (OTUs) between the groups indicated differential representation of 
some OTUs at the nominal p value of <0.05, none of differences achieved significance 
after multiple comparison correction (i.e. low FDR).  
 
In view of the above results, we sought to narrow the universe of bacteria with the 
potential of causing enteropathy in CVID. First, we took into consideration our results 
showing that low mucosal IgA levels discriminated between patients with and without 
enteropathy (Figure 2).  Second, we reasoned that since IgA is known to be protective 
against pathogens and can regulate commensal microbiota [16-18], bacterial species 
potentially contributing to disease in E-CVID patients would have increased abundance 
in E-CVID tissue compared to control tissue and would be negatively correlated with IgA 
levels. To select such bacterial candidates, we combined the results of correlations 
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between bacterial abundances and IgA gene expression with the results of enrichment 
of bacteria in E-CVID using a recently developed statistical approach [19, 20]. Thus, out 
of 582 OTUs detected in duodenal biopsies, we found 45 OTUs (FDR<20%) that were 
enriched with bacteria potentially involved in enteropathy (red dots in right lower corners 
in both panels of Figure 3d, Supplementary Table S6). 
 
Transkingdom Network Analysis Identifies Candidate Microbes Capable of 
Driving CVID Enteropathy   
 
To further identify the microbe or microbes driving CVID enteropathy, we employed 
transkingdom network analysis, an analytic method that we recently developed [20, 21] 
and successfully used to identify microbiota causing changes in host phenotypes [12, 
22]. Using this method of analysis, we integrated abundances of microbial OTUs with 
mRNA levels of host genes present in the E-CVID signature and thus formed a network 
in which microbes with strong connections to altered host genes were revealed. The 
resulting network (Figure 4A) consisted of 1474 human genes and 72 OTUs (45 
potential causal and 27 potential protective bacteria, Supplementary Table S7) from the 
microbial candidates previously identified by their association to mucosal IgA levels and 
abundancies in E-CVID (Figure 3d).   
 
Among the OTUs that were both most abundant and highly connected to human up-
regulated genes (mostly pro-inflammatory) in the majority of patients with E-CVID were 
OTUs from the Acinetobacter genus, Geobacillus genus and otu_15570 with an 
ambiguous taxonomy (Figure 4b, Supplementary Table S8). The number of edges (i.e. 
links) in the network connecting Acinetobacter, Geobacillus and otu_15570 with human 
genes was 29, 28, 28 and fold-change of enrichment in E-CVID over other groups was 
28, 3, 44 respectively (Figure 3d). Thus, these three OTUs emerged as possible 
microbes causing E-CVID (Figure 4b).   
 
Of these three OTUs, Acinetobacter was the most promising since this genus harbors 
several known pathobionts (commensal microorganisms that can become pathogens 
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under favorable circumstances [23, 24]) whereas Geobacillus and the otu_15570 
bacterium have not been previously associated with human disease.  In further studies 
to identify organisms in these groups at the species level we employed shotgun 
RNAseq rather than 16S rRNA methodology since the latter was not sufficient to 
support species resolution.  Using this approach, we verified all sequences belonging to 
the three genera and assigned them to species when possible.  We found that whereas 
shotgun RNAseq analysis did not support species resolution for Geobacillus and 
otu_15570 (Supplementary Figure S4, and Supplementary Table S9) it did reveal that 
Acinetobacter baumannii is the predominant species in the Acinetobacter organism 
genus identified in duodenal biopsies (Figure 4c; Supplementary Table S10). This 
bacterium has been found in the human intestine and can be a cause of hospital-
acquired nosocomial infection not involving the GI tract, presumably as a result of its 
resistance to antibiotic treatment [25, 26], [27]. Furthermore, analysis of the duodenal 
microbiome of patients/controls in all 3 study groups by 16S rRNA sequencing of 
duodenal biopsies showed that Acinetobacter was present in the duodenal microbiome 
in all 7 E-CVID patients, 6/8 noE-CVID patients and 3/7 controls (Figure 4d). 
Furthermore, direct association with IgA expression levels showed that Acinetobacter 
had the most significant negative correlation with IGHA1 and IGHA2 (FDR=0.016, with 
r=-0.76, r=-0.47, respectively) among all detectable taxa. Taking these results together 
with the outcome of the transkingdom network analysis, it became reasonable to 
postulate that A. baumannii, acting as a pathobiont, was a significant factor in the 
development of enteropathy in CVID patients. 
 
We next conducted in vitro experiments to determine if A. baumannii can be a 
contributing pathobionts in E-CVID.  Based on the supposition that macrophages, cells 
that we found were highly enriched in E-CVID mucosa (Figure 1d and 1e), would be the 
primary cells responding to A. baumannii and triggering a pro-inflammatory reaction in 
the CVID intestine, we determined whether A. baumannii can induce macrophages to 
display inflammatory alterations similar to those observed in CVID enteropathy tissues.  
In this experiment, we co-cultured THP-1 macrophages with A. baumannii or with a 
control bacterium for 6 h and then determined gene alterations occurring in the 
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macrophages. The control bacterium used in this experiment was Lactobacillus 
plantarum, a bacterium that was the most abundant in duodenal biopsies from E-CVID 
patients among those potentially controlled by IgA, but did not fulfill other criteria for 
candidate pathobionts (see Figure 4b and more details in M&M). We found that A. 
baumannii strongly induced expression of interferon type I (IFNB1) and CXCL9, the 
latter a chemokine involved in M1/Th1 activation (Figure S6). In addition, using global 
gene expression analysis, we found that A. baumannii induced alterations in the 
expression of 252 genes (185 Up- and 67 Down-regulated) that were highly concordant 
with the CVID enteropathy expression profi le whereas Lactobacillus plantarum did not 
(Figure 4e). Up-regulated genes included those coding for proteins involved in immune 
responses such as intracellular microbial nucleic acid sensors (AIM2, IFI16, TLR8), 
numerous IFN-dependent genes (GBP1, IRF1, STAT1, MX1, IDO1, TAP1, IFI44, OAS2, 
IFIT1, RSAD2), chemokines (CCL2, CXCL1, CXCL10), and many other innate immune 
response genes (Figure 4e). These in vitro data therefore show that A. baumannii can 
induce an immune response in macrophages consistent with the induction of the Th1-
driven inflammation that has been found in E-CVID and thus support the possibility that 
this bacterium can be a pathobiont contributing to CVID enteropathy. 
 
The Interferon Response in E-CVID Drives Inhibition of Lipid Metabolism in E-
CVID Epithelial Cells 
 
In further studies we examined the relation between the nature of the abnormal immune 
response dominating enteropathy in E-CVID and lipid malabsorption. As mentioned 
above, in our previous studies in humans [9] and in mouse model [11], metabolic 
alterations in epithelial functions were associated with elevations in both type I and type 
II interferons.  Therefore, we further investigated this phenomenon and observed  
elevated expression of several genes known to be induced by IFN type I (OAS2, MX1, 
RSAD2) or type II (GBP1, IDO1, TAP1) as well as increased expression of both types of 
IFNs themselves in E-CVID tissue (Figure 5a,b). Next, to evaluate the effects of IFNs on 
epithelium we cultured a human duodenal epithelial cell line (FHs 74 int) in the presence 
of the two types of IFNs together or separately and then assessed gene expression 
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changes for the genes from the E-CVID profile we have established in this work (Fig. 
1b).  To take a full advantage of this in vitro model and the same time to reduce its 
potential limitations we focused our analysis on gene expression signature discovered 
evaluating patients’ biopsies.  We found that alterations in the expression of 
approximately 25% of the genes in the E-CVID gene signature (p<0.05, FDR=15%) 
were consistent with the direct effect of IFNs on the epithelial cells (Figure 5c; left 
panel). Interestingly, treatment with individual interferon types regulated significantly 
fewer genes than both interferons together with 70 genes regulated by type I and 232 
by type II interferon whereas these interferons together regulated 343 genes (Figure 
5c).  
 
While most of the interferon-regulated genes (234 genes) were among those up-
regulated in the gene signature, there were 109 downregulated genes enriched for 
several metabolic processes (Supplementary Table S11). Furthermore, as in the case 
of the up-regulated genes, the magnitude of downregulation was much less pronounced 
with individual IFNs than with both of IFNs (Supplementary Figure S8). In an additional 
analysis focusing on lipid metabolism we found that among genes belonging to the 
group down-regulated by IFNs in epithelial cell culture, the majority (32 out of 43, 74%) 
had decreased expression after interferon stimulation similar to that observed in 
biopsies from CVID patients with enteropathy (Figure 5d; Supplementary Table S11). 
These genes are known to be involved in various aspects of enterocyte lipid metabolism 
such as fatty acid uptake, transport and biosynthesis (CD36, SLC27, ECHDC2, 
ACSF2), fatty acid oxidation (ACOX1, ACOX2), cholesterol binding (OSBP2, OSBPL7, 
HSD17B2), and phospholipid transport (ATP8A2, ATP8B2). To test if these effects of 
IFNs on lipid metabolic gene expression translates into functional alterations we 
measured intracellular cholesterol levels. In fact, as predicted by the transcriptomic 
alterations, we observed a consistent reduction in intracellular cholesterol levels after 
IFN treatment (Figure 5e).  Taken together, these results suggested that the up-
regulation of interferon-related genes in CVID drives changes in epithelial cell 
metabolism in this disease.  
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Discussion 
 
Gastrointestinal (GI) symptoms are diverse and relatively frequent in CVID patients  
despite IgG-replacement therapy. It has been reported that up to 50% of these patients 
exhibit various degrees of GI symptomatology and up to 15% of the patients exhibit 
CVID-associated enteropathy characterized by villous atrophy, malabsorption and 
severe diarrhea that is potentially life threatening and usually treatable only with further 
immunosuppression [7, 9].  
 
A central question that we aimed to address in the present study is why some CVID 
patients develop enteropathy and others do not. Although it was widely recognized that 
plasma cell levels and serum IgA levels were decreased in CVID patients, no clear 
distinction with respect to these features of immunodeficiency was attached to the 
presence or absence of enteropathy [1, 8].  In the current study we made the 
unexpected finding that while CVID with and without enteropathy did indeed have 
diminished serum IgA levels, most if not all of the CVID patients with enteropathy 
exhibited dramatically decreased IgA expression in the duodenal intestinal tissues 
compared to their counterparts without enteropathy. This finding strongly suggests that 
patients with enteropathy exhibit more mucosal immunodeficiency than those without 
enteropathy and are therefore more at risk for a form of gut infection that could cause 
enteropathy as extensively discussed below. Prior studies partially support this 
conclusion in that they showed that CVID patients with relatively low IgA levels were 
more prone to develop various bacterial and viral infections than other CVID patients  
[28],[29].  However, these studies did not show that low mucosal IgA levels was 
associated with enteropathy; this discrepancy may be related to the sensitivity of the 
staining procedures used in the prior studies as well as the fact that they did not 
evaluate patients by assessing mucosal Ig mRNA levels (which in this study 
corroborated the tissue staining findings).  
Finally, it should be noted that while defective mucosal IgA responses may define the 
pre-condition central to development of enteropathy in CV ID at the level of immune 
function it does not define the underlying immunologic abnormality necessary for the 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
development of this pre-condition. A possibility that requires future exploration in this 
regard is that those CVID patients with enteropathy have in common a genetically 
determined defect in B cell trafficking that impairs the migration of IgA as well as IgG-
producing B cells into the mucosal tissues. 
 
One possible caveat to the above conclusion is that enteropathy only rarely occurs in 
patients with selective IgA deficiency.  However, this can be explained by the fact that 
patients with this immunodeficiency almost invariable have B cells that produce IgA, 
albeit at a level lower than that in control individuals.  In addition, it has been reported 
that these patients produce IgG and IgM in the mucosal tissues that partially 
compensate for the lack of IgA [30],[31]. A second possible caveat is that enteropathy 
has not been reported in X-linked immunodeficiency patients who have as profound a 
deficiency in mucosal IgA levels as CVID patients with enteropathy. A possible 
explanation for this discrepancy is that CVID patients have an accompanying 
immunologic abnormality that pre-disposes them to the intense Th1-mediated immune 
response in the upper intestine that is the actual cause of the villous atrophy and 
resulting malabsorption. Evidence supporting this view comes from previous studies 
showing that cells from all CVID cells exhibit an IFN- signature as well as the present 
study which shows that duodenal tissue from CVID patients with enteropathy exhibit 
overexpression of IFN genes (see further discussion below).  This T cell abnormality 
could be a primary defect accompanying the disease or, as suggested recently, an 
abnormality secondary to lack of B cell regulation of Th1 T cell development  [32].  In 
any case, one is led to the conclusion that, while a B cell abnormality manifesting as 
mucosal IgA deficiency sets the stage for enteropathy-causing infection in CVID and 
serves as a risk factor for the latter sustained inflammation due to a robust T cell 
response is also necessary for the development of the main manifestation of 
enteropathy, villous atrophy and malabsorption. 
The above explanation of the immunologic conditions allowing the development of 
enteropathy introduces the question as to which organism could be causing CVID 
enteropathy. Early on, infection with Giardia lamblia was noted to occur with increased 
frequency in CVID and was suggested to be a cause of CVID enteropathy; however, it 
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became apparent that while eradication of this organism in CVID patients does resolve 
symptoms of the infection it does not reverse co-existing enteropathy; in addition, in the 
past decade most patients with enteropathy are free of Giardia infection [9].  In a more 
recent study of infection in CVID patients it was found that sporadic infection with a 
variety of bacterial and viral pathogens does occur in CVID, but no evidence that these 
were causative of enteropathy and in most cases the infection did not cause 
symptomatic disease [33]. A possible exception to this trend is the possibility that CVID 
is caused by norovirus infection since this organism has been found in stool and 
biopsies of some (but not all) patients with this condition [29, 33, 34]. Our molecular 
analysis of organisms associated with the duodenal specimens showed that CVID 
patients with and without enteropathy exhibited a relatively low norovirus positivity in 
biopsies (Supplementary Figure S9). This suggests that norovirus alone cannot explain 
the presence of enteropathy, at least in our patient cohort. It remains possible, however, 
that this agent is playing a role as an adjuvant to the causative organism as it can 
induce intestinal inflammation in humans and mice (reviewed in [35]).  Finally, it should 
be noted that duodenal biopsy specimens were also evaluated by PCR and whole 
genome RNA sequencing for the presence of enterovirus, adenovirus, astrovirus and 
rotovirus; only enterovirus was detected in one tissue specimen that happened to be 
positive for norovirus. 
In another study [8], it was found that the fecal microbiome of CVID patients exhibited a 
“dysbiosis” characterized by multiple alterations in the composition of the microbial 
community including both increases and decreases of several taxa compared to those 
in control individuals. In general, however, these changes in fecal microbiome did not 
differentiate patients with enteropathy from those without enteropathy and did not 
identify a specific organism as a cause of the enteropathy. In studies of the gut 
microbiome carried out here and focusing on the microbial community in the duodenum 
of CVID patients with and without enteropathy we did not observe a changed level of 
diversity compared to controls. However, a more complex sys tems biology analysis of 
these data yielded more positive results.  As detailed in Results, this involved first 
narrowing the list of possible organisms to those that both negatively correlated with 
intestinal IgA levels and that are enriched in CVID enteropathy.  Second, this involved 
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selecting among the organisms meeting these criteria to a transkingdom network 
analysis in which possible causative organisms are identified on the basis of their 
closeness (i.e., linkage) to the up-regulated host gene expression profile associated 
with enteropathy. Out of three different taxa that have higher chance to be pathobionts 
potentially contributing to enteropathy in patients with CVID one organism 
(Acinetobacter baumannii) could be identified to the species level.  
A. baumannii fulfilled several of the criteria one might expect of an enteropathy-inducing 
organism.  In fact, in vitro culture of this organism, induced Th1/M1-like gene expression 
profile in a human macrophage line that was in fact very similar to that observed in 
tissue from CVID with enteropathy (Figure 5f).  A. baumannii also has clinical features 
that would characterize a possible organism causative of enteropathy.  First, it is a 
notably antibiotic-resistant bacterium, which would fit with the fact that CVID 
enteropathy does not usually respond to antibiotic therapy. Second, although A. 
baumannii has been found in the intestine of healthy individuals [36, 37] and we 
detected this bacterium in both control individuals and patients with CVID without 
enteropathy, this microbe has been associated with wound, lung and blood i nfections in 
soldiers and patients in intensive care units [38-42].  Interestingly, in a very recent study 
it was found that an Acinetobacter genus was associated with inflammatory cellular and 
gene expression profi les in IBD patients [43]; this provides further support for the 
potential role of these bacteria in gut inflammation 
 
The above studies supporting the idea that A. baumannii is acting as a pathobiont in 
CVID enteropathy notwithstanding, the possibility exists that other bacteria could also 
have this role. This follows from the fact that the transkingdom network analysis 
identified other possible pathobionts in CVID, including , Geobacillus, a bacterium that 
shares some genetic properties with segmented fi lamentous bacteria (SFB) and that is 
well known as an inducer of pro-inflammatory cytokines in the mouse small intestine 
[44] .  Thus, while our study, together with previous mouse data [11], supports the 
concept that CVID enteropathy is possibly caused by a pathobiont in the upper GI tract 
and identified A. baumannii as one such pathobiont, it is likely that other pathobionts will 
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be identified which also have this role  and are the cause of enteropathy in CVID 
patients in which this organism is not found. 
In the present studies we performed extensive global gene expression profi ling that 
confirmed our previous finding that a Th1-like inflammatory process underlies CVID 
enteropathy [9]. In addition, it led to the further insight that both type I and II interferons 
are involved (Fig. 5). Interestingly, these findings coincide with a previous study 
showing up-regulation of IFN-driven gene expression in whole blood cell populations is 
a feature of CVID patients with a variety of inflammatory complications including those 
with and without gastrointestinal inflammation [45]. Confirming our previous mouse 
studies we identify in humans that the shift from metabolic to immune/pro-inflammatory 
in the small intestine is associated with the development of enteropathy. In addition, we 
now show that the type I and type II interferons above are responsible for this shift  and 
that, for instance, lipid transport gene expression and intracellular cholesterol levels are 
directly and adversely affected by interferons. It should be noted, however, that while 
these metabolic alterations may contribute to the malabsorption characterizing CVID 
enteropathy the latter is mainly due to cytotoxic effects on epithelial cells arising from 
the inflammation. 
Overall, in this work, we present evidence that CVID enteropathy is uniquely 
characterized by a severe deficit in mucosal IgA secretion, an abnormality that sets the 
stage for possible colonization and infection by one or more commensal organisms 
acting as pathobionts in the IgA-deficient mucosal environment.  We have identified A. 
baumannii as one such possible pathobionts.  CVID enteropathy is also uniquely 
characterized by a gene profile in which IFN gene expression is greatly increased 
whereas metabolic gene expression is greatly decreased. This abnormality may 
contribute to the development of enteropathy by facilitating the robust interferon-
mediated response necessary to induce villous atrophy and malabsorption. 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
Material and Methods 
Patients 
 
Eligible patients older than 18 years of age had a diagnosis of common variable 
immunodeficiency according to established criteria of a medical history of mucosal 
infections, decreased immunoglobulin levels 2 standard deviations below the norm and 
decreased humoral vaccine challenge responses. CVID patients with a concomitant 
history of chronic diarrhea or unexplained weight loss greater than 5% of total body 
weight over the previous 6 months with changes in more than one parameter consisting  
of body mass index, serum albumin, serum protein and number of liquid stools  were 
classified in the CVID enteropathy cohort of patients (N=7, 4 males, 3 females). CVID 
patients without enteropathy constituted the no enteropathy CVID group (N=8, 2 male, 6 
females). Additional control patients consisted of patient population without acute 
disease, CVID or GI pathology disease but, could include patients with irritable bowel 
syndrome (N=7, 3 males, 4 females). Patients were additionally classified based upon 
duodenal histopathology (see Supplementary Table S14 and Supplementary Table 
S15). All eligible patients had negative stool testing for pathogens (Salmonella, Shigella, 
Yersinia, Campylobacter, Vibrio, Escherichia coli O157/H7, Cryptosporidia, Cyclospora, 
Microsporidia, and Giardia) and Clostridia difficile toxin, negative hydrogen breath test, 
were on no immunomodulatory agents for the preceding 4 months, and were human 
immunodeficiency virus (HIV) negative. CVID patients with enteropathy or CVID 
patients without enteropathy had received antibiotic therapy in the year prior to this 
study for a variety of clinical conditions which included small bowel intestinal 
overgrowth, C. difficile intestinal infection, sinusitis, and pulmonary prophylaxis 
treatment. Patients in these groups did not receive any antibiotic therapy in the three 
months prior to analysis (except for one patient in each of the CVID with enteropathy 
and without enteropathy groups which received antibiotics on a continued basis for lung 
prophylaxis treatment). The enteropathy in the CVID patient who receiving continued 
antibiotic therapy did not have a change in his enteropathy.  All protocol and informed 
consent procedures were approved by the National Institute of Allergy and Infectious 
Disease and Oregon State University Institutional Review Boards. 
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Patient Peripheral Cell Lymphophenotyping 
 
Peripheral blood cells (3 mL EDTA anticoagulated samples) were stained for flow 
cytometry using a whole- blood lysis method and analyzed on a CANTO2 (Becton 
Dickinson Biosciences, San Jose, CA). CD3+T cells and T-cell subsets were identified 
by directly conjugated monoclonal antibodies anti-CD3, anti-CD4, anti- CD8.  B cells 
and B cell subsets were identified by directly conjugated monoclonal antibodies  anti -
CD20; and memory B cells with  anti-CD27;  directly conjugated, murine IgG1 was used 
to ascertain background staining. All monoclonal antibodies were obtained from Becton 
Dickinson Biosciences (San Diego, CA). Lymphocyte gate was established using 
forward and side scatter with list mode parameters collected for 106 lymphocytes. To 
calculate absolute numbers of each lymphocyte subset, the proportion of cells staining 
positive was multiplied by the absolute peripheral blood lymphocyte count. Peripheral 
blood obtained from study control  individuals was stained and analyzed to establish 
comparison normal control  values. 
 
Exome Sequencing 
 
Targeted exome sequencing was performed at the National Institutes of Health facility 
for genes known to be correlated with CVID using the Ion Torrent AmpliSeq RDY 
Exome Kit (Life Technologies) and the Ion Chef and Proton instruments (Life 
Technologies). Briefly, 100 ng of gDNA was used as the starting material for the 
AmpliSeq RDY Exome amplification step following the manufacturer’s protocol. Library 
templates were clonally amplified and enriched using the Ion Chef and the Ion PI Hi -Q 
Chef Kit (Chef package version IC.4.4.2, Life Technologies), following the 
manufacturer’s protocol. Enriched, templated Ion Sphere Particles were sequenced on 
the Ion Proton sequencer using the Ion PI chip v3 (Life Technologies). Read mapping 
and variant calling were performed using the Ion Torrent Suite software v4.4.2. In short, 
sequencing reads were mapped against the UCSC hg19 reference genome usi ng the 
Torrent Mapping Alignment Program (TMAP) map4 algorithm. SNPs and INDELS were 
called by the Torrent Variant Caller plugin (v.4.414-1) using the ‘Generic-Proton-Germ 
Line – Low Stringency’ configuration. Only reads that were unambiguously mapped 
were used for variant calling. Variants were annotated using ANNOVAR 
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(http://annovar.openbioinformatics.org/). Data mining, biological interpretation, and 
candidate gene discovery were performed using various online tools, including The 
Database for Annotation, Visualization and Integrated Discovery (DAVID, 
https://david.ncifcrf.gov), and GeneCards (http://www.genecards.org). Target coverage 
was evaluated using the Torrent Coverage Analysis plugin (v.4.414-1), and the output 
was further evaluated using in-house, custom Perl scripts. 
 
 
Endoscopic Biopsy  
Endoscopic biopsy specimens were fixed in 10% formalin prior to paraffin embedding 
and routine staining with H&E. Biopsy specimens were reviewed by a gastrointestinal 
pathologist who was masked to the clinical status of the patients. Biopsy specimens 
were labeled as nodular lymphoid hyperplasia (NLH) if germinal centers were present, 
intraepithelial lymphocytosis if there were greater than 5 lymphocytes per 20 epithelial 
cells, and noted for apoptosis if there were greater than 5 apoptotic epithelial cells per 
10 glands. CVID patients with enteropathy were noted to exhibit concomitant histologic 
changes in the duodenum which included villus blunting, flattening/atrophy, an 
increased number of intraepithelial lymphocytes, the appearance of increased 
polymorphonuclear cells and lymphocytes in the lamina propria.  
 
Immunohistochemistry and image analysis 
Paraffin embedded biopsy tissues were and cut into 5 μm sections. Antigen retrieval 
was performed at 90C for 20 min and sections were blocked with bovine serum 
albumin following by staining with anti-IgA (Abcam ab124716) or anti-CD8 (Dako 
M710301-2) both at a dilution of 1:100. Sections were developed with 3,3'-
diaminobenzidine (DAB), and counterstained with hematoxylin by HistoServ 
(Germantown, MD). Slides were imaged using a Leica DM E microscope. For IgA 
quantification, DAB+ area and total tissue area were quantified from 5-7 randomly 
selected fields representative of total tissue area. For CD8+ area, the epithelial layer 
was manually selected from 5-7 randomly fields and DAB+ area and total tissue area 
were quantified from this selected epithelial area. All image selection, color 
deconvolution and area quantifications were performed using Fiji [46]. 
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Shotgun RNA sequencing and 16S rRNA gene sequencing 
Total RNA from biopsies was isolated using TotalPrep RNA/DNA kit (Qiagen) after 
mechanical homogenization with Omni rotor followed by Qiashredder (Qiagen). For 
analysis of bacterial 16S rRNA gene expression, 1 microgram of total RNA was reverse 
transcribed using VILO cDNA synthesis kit with random primers (Invitrogen) and this 
cDNA was used for qPCR with universal bacterial primers and for 16S rRNA library prep 
and then sequenced on MiSeq instrument according to a previous protocol [22]. For 
human gene expression and shotgun metagenomics, libraries were prepared using 
ScriptSeq™ Complete Gold Kit (Epicentre/Illumina) according to manufacturer’s 
instructions including removal of rRNA. These libra ries were sequenced on HiSeq2000 
instrument (Illumina) with four samples per lane resulting in ~50*10^6 reads per sample.  
 
RNA-seq gene expression analysis  
Forward read sequences with at least one ambiguous nucleotide were filtered out by 
prinseq. Trimmometic was used to trim Illumina adaptor sequences (parameters: seed 
mismatches:1, palindrome clip threshold: 10 and simple clip threshold: 10), to remove 
leading and trailing low-quality bases (below quality 3), to scan the read with a 4 -base 
wide sliding window, and to cut when the average quality per base drops below 20 and 
to drop reads that below 60 bases long. Reads were aligned to human genome and 
transcriptome (ENSEMBLE release-70) using Tophat with default parameters. Number 
of reads per million for human genes were counted using HTSeq. Genes that were 
detected in at least three samples were included in downstream analysis using BRB 
ArrayTools and normalized by quantile normalization.  
 
For signature finding, differentially expressed genes were defined by comparing three 
groups using univariate test requiring p<0.05 and FDR <0.2, followed by pairwise 
comparisons using t-test, FDR<0.1 and Venn Diagram analysis. See details in 
Supplementary Figure 1.  
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Gene Ontology enrichment analysis of Biological Processes (BP_FAT) was performed 
using DAVID Bioinformatics Resources 6.7 with threshold gene count 2 and enrichment 
score p-value <0.01[47]. 
For immunoglobulin expression analysis we retrieved quantile normalized gene 
expression levels for IGHA1, IGHA2, IGHM, IGHG1, IGHG2, IGHG3, IGHG4. 
 
Cell type enrichment analysis 
For M1 and M2 microphages, we used the gene signatures from work of Martinez and 
co-workers [14]. For all other cell types, we inferred gene signatures using data from D-
map [13]. The signature of a given cell type was defined as a group of genes with at 
least two-fold higher expression (FDR<0.1) than in other cell types (e.g. T lymphocytes 
vs other hematopoietic cells), and followed by subdivision of this parent signature by 
comparing a given cell type with closely related cell types (e.g. naïve vs memory T 
lymphocytes). Enrichment of gene signatures was performed using Gene Set 
Enrichment Analysis (GSEA) 2-2.2.3 with default parameters [48]. 
 
Microbiome 16S gene analysis 
The raw forward-end fastq reads were quality-filtered, demultiplexed and analyzed 
using ‘quantitative insights into microbial ecology’  (QIIME). For quality filtering, the 
default parameters of QIIME were maintained in which reads containing ambiguous 
base calls and containing fewer than 187 nt (75% of 250 nt) of consecutive high-quality 
base calls, were discarded. Additionally, reads with three consecutive low-quality bases 
were truncated. The samples sequenced were demultiplexed using 12 bp barcodes, 
allowing 1.5 errors in the barcode. UCLUST was used to choose OTUs with a threshold 
of 97% sequence similarity against Green gene database (version gg_12_10) A 
representative set of sequences from each OTU were selected for taxonomic 
identification of each OTU by selecting the cluster seeds. The Greengenes OTUs 
(version gg_12_10) reference sequences (97% similarity) were used for taxonomic 
assignment using BLAST with E_value 0.001. Raw read counts of OTUs were 
normalized against total number of reads that passed quality filtration to generate 
relative abundance of OTUs. DNA amount of an OTU in a sample was calculated by 
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multiplying relative abundance of the OTU by total amount of bacterial DNA in the 
corresponding sample. Differentially abundant OTUs were identified using univariate-
test in BRB array tools’ ‘class comparison between groups of arrays’ modules. Beta 
diversity was calculated using QIIME script beta_diversity.py using option -m 
binary_pearson followed by principal_coordinates.py to generate principle coordinates. 
Alpha diversity was calculated using QIIME script alpha_diversity.py for calculating 
shannon index on randomly subsampling 15003 sequences for each sample. Tree of 
life graph was generated using the online tool iTOL (http://itol.embl.de/). 
Network analysis and causal inference 
Overall procedure is described in [49]. In brief, human gene–gene network was 
reconstructed using following steps. First, for each pair of genes/OTUs, three Pearson 
correlation coefficients and p-values are calculated using abundance levels of each of 
the three groups of E-CVID, NoE-CVID, Controls. Second, Fisher combined p-value is 
calculated from three p-values using Fisher’s combined probability test. FDR value is 
calculated from the combined p-value. The sign of correlation coefficients in three 
groups should be consistent (all positive correlation or all negative correlation across 
three groups). Also, we selected correlations that had sign of correlation consistent with 
possibility of causal relations between genes[19]. Third, human gene-gene network was 
generated by requiring all p-values of correlation coefficient from three groups <0.05 
and combined FDR<0.1. Three human gene expression networks corresponding to 
three groups of samples were generated by selection and inclusion of gene pairs as 
following: Individual p-value of correlation within each group was smaller than 0.2; 
combined FDR smaller than 0.15. 
The bi-partite betweenness centrality calculation is similar to conventional betweenness 
centrality except that shortest paths are calculated only between nodes belonging to two 
different groups of nodes and not between any nodes within the same subnetwork [12, 
20]: 
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Where s and t are two nodes belonging to two different subnetworks,   is the total 
number of shortest paths from node s to node t and is the number of those paths 
that pass through v. 
We used the scaled betweenness centrality for each network (by requiring individual p-
value <0.05, 0.1 or 0.2)  using the formula: 
 
 
 
 
Reconstruction and interrogation of transkingdom network 
To select OTUs potentially IgA dependent and differentially represented in E-CVID, 
Pearson correlation was calculated between OTU levels and expressions of IgA1 and 
IgA2, respectively. P values from two correlation analysis were integrated with t-test 
result from comparisons between E-CVID and HV using Fisher’s test followed by FDR 
calculations. OTUs that had FDR <=20% were selected for further integration into 
transkingdom network.  
For human gene-microbe transkingdom network reconstruction, we applied the same 
procedure as for the gene-gene network requiring FDR <0.1. In order to identify 
potential candidate microbes that promote inflammation we interrogated a transkingdom 
network that represent a statistical model of interaction between microbiome and host 
transcriptome [20]. We thought that commonly used network parameters such degree of 
a given node would not be appropriate to ask our biological question. Therefore, in 
order to rank OTUs by strength of their potential influence on the host we focused our 
analysis and counted number of direct links (edges) between a given OTU and 
upregulated genes in transkingdom network. 
Identification of species for OTUs that are potential stimulators of human up-
regulated immune genes 
Transkingdom network analysis revealed several OTU candidates that are abundant in 
E-CVID and had many connections to human up-regulated immune genes. They are 
also potential regulators of human immune gene expression. However, 16S-based OTU 
taxa assignment of these candidates didn’t reach species level, thus limited our ability to 
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experimentally test their functions. To better characterize the candidate OTUs, we 
utilized shotgun metatranscriptomic data derived from the same samples to profile 
abundance of species from the same most detailed taxa level (genus/family/order) of 
the candidate OTUs. We assign reads from shotgun metatranscriptomic to species 
based on our previous procedure [12]. Briefly, we aligned reads to reference protein 
database then used MEGAN5 to transfer the taxa of proteins  to the reads that aligned to 
them. For the OTU denovo96904 (assigned to genus Geobacillus), we found that there 
are four Geobacillus species with similar abundance detected in the samples 
(Supplementary Figure S4). In this case there was not enough information to determine 
which species denovo96904 corresponds to. For the OTU denovo15570 (assigned to 
order Stramenopiles), we didn’t detect species from this order using shotgun 
metatranscriptomic data. We then took the representative 16s rRNA amplicon sequence 
of this OTU to search against NCBI nt database to figure out which species it came 
from. The result (Supplementary Table S9) indicated that there were many species 
sharing the exact same 16s rRNA region, including Cyclotella and uncharacterized 
bacterium. Thus, we were unable to obtain species information for the two candidates 
except the Acinetobacter OTU denovo56853 (Acinetobacter baumannii).  
Technical parameters utilized for shotgun analysis of RNA-seq data to establish 
individual microbes corresponding to candidate OTUs 
Sequences with at least one ambiguous nucleotide were filtered out by prinseq. 
Trimmomatic was used to fi lter out Illumina adaptor sequences (under parameters: seed 
mismatches: 1, palindrome clip threshold: 10 and simple clip threshold: 10), to remove 
leading and trailing low quality bases (below quality 3), to scan the read with a 4 -base 
wide sliding window, and to cut when the average quality per base drops below 20 and 
to drop reads that are below 60 bases long. Human sequences were filtered out by 
aligning reads against human genome (hg19) using Bowtie2 under default parameters. 
Around 82% of original reads passed filter steps and subject to downstream analysis. 
Taxonomic assignment of reads was carried out using DIAMOND a lignment against the 
integrated nonredundant protein database (ftp://ftp.ncbi.nlm.nih.gov/blast/db/nr.tar.gz).  
DIAMOND alignment hits with e-values larger than 0.001 were filtered out, and for each 
read, top 20 hits were retained to distinguish taxonomic groups. The taxonomical level 
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of each read was determined by the lowest common ancestor (LCA)-based algorithm 
that was implemented in MEGAN4. In this algorithm, if a read had significant alignment 
hit in many species, it was assigned to the LCA instead of a species. Megan4 
parameters were set to: min support=1, min score=50, min complexity=0.44, top 
percent=10, win score=0. 
 
Selection of control bacterium 
To select bacterial candidate that would serve as a control for A. baumannii as common 
commensal bacteria in duodenum that does not contribute to E-CVID according to our 
analysis. We wanted this bacterium being similar A. baumannii to for all features except 
inflammation promotion properties. Thus, top OTU (operational taxonomic unit) was 
dramatically enriched on biopsies from E-CVID patients (fold change 2225.3), 
negatively correlates with IgA genes(r=-0.351, r=-0.47; FDR<0.087), but did not connect 
much with proinflammatory genes in the network (Figure 4b; and Supplementary Figure 
S5). This candidate was OTU from Lactobacillus genus. Shotgun RNA-SEQ taxa 
assignment indicates multiple species with similar number of reads assigned. Thus, for 
each species detected by shotgun RNA-SEQ, we correlated their abundance across 
samples with the abundance of the candidate lactobacillus OTU and found the species 
Lactobacillus plantarum has highest correlation to the candidate OTU. Thus, we 
selected this species as negative control in regulating human up-regulated in E-CVID 
genes.  
Bacterial cultures  
Acinetobacter baumannii (ATCC 17978 or AB5075 from A. baumannii Transposon 
Mutant Library, UW Genome Sciences) was streaked out from -80°C on Luria-Bertani 
(LB) agar (BD) plate and incubated overnight at 37°C. To determine the optical density 
(OD600) and its corresponding colony forming units (CFU), one colony from this plate 
was inoculated in 10 ml of LB broth (Fisher BioReagents), and incubated at 37°C with 
shaking at 200 rpm. Every 2 hours, OD600 of the broth was verified and bacteria were 
plated in LB agar in serial dilutions. After overnight incubation, the CFU was calculated 
and used to establish a growth curve for the relationship between OD600 and CFU. For 
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co-incubation with human cells, one colony from the LB agar plate was inoculated in 10 
ml LB broth, incubated at 37°C with shaking at 200 rpm for 8-9 hours and OD600 was 
checked. This OD600 was used to interpolate the CFU in the broth using the 
established growth curve.  
Lactobacillus plantarum (DSM 12028) was streaked out from -80°C on de Man, Rogosa 
and Sharpe (MRS) agar (Hardy Diagnostics) plate and incubated overnight in anaerobic 
conditions using GasPak EZ Gas Generating Container Systems (BD, Catalog# 
260001) at 37°C. The correspondence between CFU and OD600 was established using 
the same method as for A. baumannii except using MRS medium and anaerobic 
conditions without shaking. To co-incubate the cells, one colony from the agar plate was 
inoculated in 10 ml MRS broth (Hardy Diagnostics) and incubated anaerobically as 
above for 8-9 hours. OD600 was checked and used to determine CFU. 
 
Co-incubation of bacteria with THP-1 Cells  
Human myelomonocytic leukemia cells line THP-1 (ATCC TIB-202) was grown in RPMI 
1640 medium (Gibco/Thermo Fisher Scientific, Catalog # 11875093) with 10% Fetal 
Bovine Serum (FBS) and 1% Penicillin-Streptomycin (P/S). For differentiation, 2.5x10^5 
cells per well (500 ul per well) were seeded in 24 well plate for 48 hours with phorbol 
12-myristate 13-acetate (PMA-Sigma) at 50ng/ml, after which medium was changed 
and followed by 24-hour resting period. After medium was removed, 2.5x10^5 CFU of 
either bacterium (1:1 MOI, multiplicity of infection) suspended in 500 ul of RPMI (without 
P/S) were added to cells. As a negative control, RPMI (without P/S) was put in the 
control wells. After 6 hours of co-incubation, medium was removed from all wells, cells 
were lysed using RLT buffer (Qiagen) and stored immediately in -80C for RNA isolation. 
RNA was extracted using RNeasy, QIAshredder and DNase in QIAcube (all from 
Qiagen) automated system as per the recommended protocol. cDNA synthesis was 
performed using qScript cDNA synthesis kit (Quantabio) as per the recommended 
protocol. Quantitative PCR (qPCR) was done using Perfecta SYBR Green FastMix 
(Quantabio) and Applied Biosystems RT-PCR platform. TMEM59 was used as the 
control gene selected from RNAseq data on the basis of low variability across 
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stimulated and control cells. RNA library prep for sequencing was performed as 
described below for intestinal epithelial cells.  
 
Intestinal epithelial cell cultures  
Human epithelial cell line (FHs 74 Int) was acquired from ATCC and maintained 
according to ATCC protocol using Hybri-Care Medium (cat# ATCC® 46-X™) with 
addition of 10% FBS (ATCC, cat# 30-2020, lot: 62144240), 5% Penicillin Streptomycin 
(Corning, REF 30-002-CI) and 30 ng/ml epidermal growth factor (EGF; Tonbo 
Biosciences, cat# 21-8356-M001). Passages used in experiments were P5-7. 
FHs 74 Int maintained in Hybri-Care Medium (10% FBS, 5% penicillin Streptomycin, 
and 30 ng/ml EGF) was split according to ATCC protocol and seeded into 96 wells 
plates with 20 000 cells/well density (200 ul of media per well). 24 h after seeding into 
plate cells were stimulated with one of the following: interferon alpha (Universal Type I 
Interferon, Pbl assay science, cat# PHC4044), IFN gamma (Recombinant Human 
Interferon – gamma, Gibco, cat# PHC4031), IFN alpha and IFN gamma, or media 
(negative control). Stimulation concentrations of interferons used were: 500 units/mL for 
interferon alpha, 100 units/mL for IFN gamma. Cells were collected by lysis with RLT 
buffer (Qiagen, cat# 79216) 48 h after stimulation. RNA was extracted with RNeasy Mini 
Kit (Qiagen, cat# 74106) according to the manufacturer’s protocol, DNase treatment 
was not included as additional step.  
For RNA sequencing library preparation, 500 to 1000 ng of total RNA was used with 
Wafergen Biosystems PrepX RNA-Seq Sample and Library Preparation Kits for the 
Apollo 324 NGS Library Prep System and sequenced on Illumina HiSeq 3000 (150 bp, 
single end) in the pool of total 28 samples per HiSeq lane. RNAseq data processing 
was performed as described above for biopsies. For comparison to E-CVID, expression 
of genes from E-CVID signature was compared between unstimulated cells and cells 
stimulated with both interferons as specified above. Genes that passed p value of 0.05 
(FDR<0.15) and presented same direction of change as in E-CVID were selected as 
concordant. 
Cells were lysed 48 h after IFNs stimulation using RLT Buffer (Qiagen). Concentrations 
of RNA measured with Qubit RNA BR Assay Kit (Life Technologies, cat#Q10211). 
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cDNA prepared using iScript (Rio-Rad, cat# 1708891). Quantitative Real-Time PCR 
was done for the samples using QuantiFast SYBR Green PCR Kit (Qiagen, cat# 
204056). qRT PCR set up used: samples were heated to 95°C, followed by 40 cycles of 
95°C for 10 sec and 60°C for 30 sec. House-keeping gene used for normalization 
(SRSF11) was selected according to the procedure described in previous publication 
[50]. For list of primers see Supplementary Table S12. 
Measurements of total cholesterol concentrations in FHs 74 Int cells 
Before been collected, cells in each well were washed with PBS and then lysed with 
Lysis Buffer from Amplex® Red Cholesterol Assay Kit (Invitrogen, cat#A12216), 
sonicated on ice 2 times 10 s each. Total cholesterol concentrations were measured 
using Amplex® Red Cholesterol Assay Kit (Invitrogen, cat# A12216) and MyQubit 
Amplex® Red Cholesterol Assay Protocol (MAN0007532). Protein concentrations were 
measured in the same lysates using Qubit® Protein Assay Kit (Life Technologies, cat# 
Q33211) following the manufacturer’s protocol (MAN0002349). Normalization of 
cholesterol concentration levels was done by dividing acquired total cholesterol 
concentrations by protein concentrations for the same sample. 
 
Norovirus detection in duodenal biopsies 
Norovirus strains were genotyped by partial nucleotide sequencing of the polymerase 
gene. Briefly, total RNA isolated from duodenal biopsies was reverse transcribed and 
fragments of the norovirus polymerase gene were amplified using primers designed to 
detect both sapo- and noroviruses [51]. In case of PCR products of expected size, they 
were purified using PCR MinElute kit (Qiagen) and sequenced using Sanger 
sequencing in ABI 3730 machine to confirm the norovirus.  Derived nucleotide 
sequences were submitted to the online Norovirus Genotyping Tool 
(http://www.rivm.nl/mpf/norovirus/typingtool). In addition, to identify closely related 
strains, the nucleotide sequences were compared with those available in GenBank 
using BLAST software (http://blast.ncbi.nlm.nih.gov).   
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Data Sharing 
All sequencing data were deposited to European Nucleotide Archive under accession 
number PRJEB18593. 
 
Author Contributions 
Conceived original idea, obtained funding, supervised the study, contributed to 
interpretation of all results and wrote the manuscript (NS, AM, WS, IJF); participated in 
patient enrollment, collection of clinical samples, collection and analysis of clinical data 
(WS, IJF, KMR, MQ, MY); performed experiments, analyzed non-large scale data (DV, 
RLG, MG, SVP, EP, SS); developed and performed microbiome and transcriptome data 
analyses including causal inference, wrote corresponding parts of the manuscript (XD, 
NS, AM); supervised all experiments and data analysis (NS, AM); all authors 
contributed and approved manuscript. 
 
Acknowledgements 
This research was supported by the grant NIH U01 AI109695 and by the Intramural 
Research Program of the NIH, NIAID (MY, IJF, WS). NS was also supported by NIH 
R01 DK103761. We thank Oregon State University Center for Genome Research and 
Biocomputing (CGRB) for sequencing services and technical support. 
This project also has been funded in part with federal funds from the National Cancer 
Institute, National Institutes of Health, under Contract No. HHSN261200800001E. The 
content of this publication does not necessari ly reflect the views or policies of the 
Department of Health and Human Services, nor does mention of trade names, 
commercial products, or organizations imply endorsement by the U.S. Government.  
 
References 
 
[1] F.A. Bonilla, I. Barlan, H. Chapel, B.T. Costa-Carvalho, C. Cunningham-Rundles, M.T. de la 
Morena, F.J. Espinosa-Rosales, L. Hammarstrom, S. Nonoyama, I. Quinti, J.M. Routes, M.L. 
Tang, K. Warnatz, International Consensus Document (ICON): Common Variable 
Immunodeficiency Disorders, The journal of allergy and clinical immunology. In practice, 4 
(2016) 38-59. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
[2] R. Ameratunga, M. Brewerton, C. Slade, A. Jordan, D. Gillis, R. Steele, W. Koopmans, S.T. 
Woon, Comparison of Diagnostic Criteria for Common Variable Immunodeficiency 
Disorder, Frontiers in Immunology, 5 (2014). 
[3] S. Jolles, The variable in common variable immunodeficiency: a disease of complex 
phenotypes, The journal of allergy and clinical immunology. In practice, 1 (2013) 545-556; 
quiz 557. 
[4] J.S. Orange, J.T. Glessner, E. Resnick, K.E. Sullivan, M. Lucas, B. Ferry, C.E. Kim, C. Hou, F. 
Wang, R. Chiavacci, S. Kugathasan, J.W. Sleasman, R. Baldassano, E.E. Perez, H. Chapel, C. 
Cunningham-Rundles, H. Hakonarson, Genome-wide association identifies diverse causes 
of common variable immunodeficiency, The Journal of allergy and clinical immunology, 127 
(2011) 1360-1367.e1366. 
[5] H. Chapel, M. Lucas, M. Lee, J. Bjorkander, D. Webster, B. Grimbacher, C. Fieschi, V. Thon, 
M.R. Abedi, L. Hammarstrom, Common variable immunodeficiency disorders: division into 
distinct clinical phenotypes, Blood, 112 (2008) 277-286. 
[6] G. Mouillot, M. Carmagnat, L. Gerard, J.L. Garnier, C. Fieschi, N. Vince, L. Karlin, J.F. 
Viallard, R. Jaussaud, J. Boileau, J. Donadieu, M. Gardembas, N. Schleinitz, F. Suarez, E. 
Hachulla, K. Delavigne, M. Morisset, S. Jacquot, N. Just, L. Galicier, D. Charron, P. Debre, E. 
Oksenhendler, C. Rabian, D.S. Group, B-cell and T-cell phenotypes in CVID patients correlate 
with the clinical phenotype of the disease, Journal of clinical immunology, 30 (2010) 746-
755. 
[7] G. Malamut, V. Verkarre, F. Suarez, J.F. Viallard, A.S. Lascaux, J. Cosnes, Y. Bouhnik, O. 
Lambotte, D. Bechade, M. Ziol, A. Lavergne, O. Hermine, N. Cerf-Bensussan, C. Cellier, The 
enteropathy associated with common variable immunodeficiency: the delineated frontiers 
with celiac disease, The American journal of gastroenterology, 105 (2010) 2262-2275. 
[8] S.F. Jorgensen, M. Troseid, M. Kummen, J.A. Anmarkrud, A.E. Michelsen, L.T. Osnes, K. 
Holm, M.L. Hoivik, A. Rashidi, C.P. Dahl, M. Vesterhus, B. Halvorsen, T.E. Mollnes, R.K. Berge, 
B. Moum, K.E. Lundin, B. Fevang, T. Ueland, T.H. Karlsen, P. Aukrust, J.R. Hov, Altered gut 
microbiota profile in common variable immunodeficiency associates with levels of 
lipopolysaccharide and markers of systemic immune activation, Mucosal immunology, 9 
(2016) 1455-1465. 
[9] P.J. Mannon, I.J. Fuss, S. Dill, J. Friend, C. Groden, R. Hornung, Z. Yang, C. Yi, M. Quezado, 
M. Brown, W. Strober, Excess IL-12 but not IL-23 accompanies the inflammatory bowel 
disease associated with common variable immunodeficiency, Gastroenterology, 131 (2006) 
748-756. 
[10] M. Cols, A. Rahman, P.J. Maglione, Y. Garcia-Carmona, N. Simchoni, H.B. Ko, L. Radigan, 
A. Cerutti, D. Blankenship, V. Pascual, C. Cunningham-Rundles, Expansion of inflammatory 
innate lymphoid cells in patients with common variable immune deficiency, The Journal of 
allergy and clinical immunology, 137 (2016) 1206-1215 e1201-1206. 
[11] N. Shulzhenko, A. Morgun, W. Hsiao, M. Battle, M. Yao, O. Gavrilova, M. Orandle, L. 
Mayer, A.J. Macpherson, K.D. McCoy, C. Fraser-Liggett, P. Matzinger, Crosstalk between B 
lymphocytes, microbiota and the intestinal epithelium governs immunity versus 
metabolism in the gut, Nature medicine, 17 (2011) 1585-1593. 
[12] A. Morgun, A. Dzutsev, X. Dong, R.L. Greer, D.J. Sexton, J. Ravel, M. Schuster, W. Hsiao, P. 
Matzinger, N. Shulzhenko, Uncovering effects of antibiotics on the host and microbiota 
using transkingdom gene networks, Gut, 64 (2015) 1732-1743. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
[13] N. Novershtern, A. Subramanian, L.N. Lawton, R.H. Mak, W.N. Haining, M.E. McConkey, 
N. Habib, N. Yosef, C.Y. Chang, T. Shay, G.M. Frampton, A.C. Drake, I. Leskov, B. Nilsson, F. 
Preffer, D. Dombkowski, J.W. Evans, T. Liefeld, J.S. Smutko, J. Chen, N. Friedman, R.A. Young, 
T.R. Golub, A. Regev, B.L. Ebert, Densely interconnected transcriptional circuits control cell 
states in human hematopoiesis, Cell, 144 (2011) 296-309. 
[14] F.O. Martinez, S. Gordon, M. Locati, A. Mantovani, Transcriptional profiling of the 
human monocyte-to-macrophage differentiation and polarization: new molecules and 
patterns of gene expression, Journal of immunology (Baltimore, Md. : 1950), 177 (2006) 
7303-7311. 
[15] K. Washington, T.T. Stenzel, R.H. Buckley, M.R. Gottfried, Gastrointestinal pathology in 
patients with common variable immunodeficiency and X-linked agammaglobulinemia, The 
American journal of surgical pathology, 20 (1996) 1240-1252. 
[16] A.J. Macpherson, E. Slack, The functional interactions of commensal bacteria with 
intestinal secretory IgA, Current opinion in gastroenterology, 23 (2007) 673-678. 
[17] O. Pabst, New concepts in the generation and functions of IgA, Nature reviews. 
Immunology, 12 (2012) 821-832. 
[18] N.J. Mantis, S.J. Forbes, Secretory IgA: arresting microbial pathogens at epithelial 
borders, Immunological investigations, 39 (2010) 383-406. 
[19] A. Yambartsev, M.A. Perlin, Y. Kovchegov, N. Shulzhenko, K.L. Mine, X. Dong, A. Morgun, 
Unexpected links reflect the noise in networks, Biology direct, 11 (2016) 52. 
[20] X. Dong, A. Yambartsev, S.A. Ramsey, L.D. Thomas, N. Shulzhenko, A. Morgun, Reverse 
enGENEering of Regulatory Networks from Big Data: A Roadmap for Biologists, 
Bioinformatics and biology insights, 9 (2015) 61-74. 
[21] R. Greer, X. Dong, A. Morgun, N. Shulzhenko, Investigating a holobiont: Microbiota 
perturbations and transkingdom networks, Gut microbes, 7 (2016) 126-135. 
[22] R.L. Greer, X. Dong, A.C. Moraes, R.A. Zielke, G.R. Fernandes, E. Peremyslova, S. 
Vasquez-Perez, A.A. Schoenborn, E.P. Gomes, A.C. Pereira, S.R. Ferreira, M. Yao, I.J. Fuss, W. 
Strober, A.E. Sikora, G.A. Taylor, A.S. Gulati, A. Morgun, N. Shulzhenko, Akkermansia 
muciniphila mediates negative effects of IFNgamma on glucose metabolism, Nature 
communications, 7 (2016) 13329. 
[23] A.Y. Peleg, H. Seifert, D.L. aterson, Acinetobacter baumannii: emergence of a 
successful pathogen, Clinical microbiology reviews, 21 (2008) 538-582. 
[24] L.C. Antunes, P. Visca, K.J. Towner, Acinetobacter baumannii: evolution of a global 
pathogen, Pathogens and disease, 71 (2014) 292-301. 
[25] A. Pistiki, I. Galani, E. Pyleris, C. Barbatzas, M. Pimentel, E.J. Giamarellos-Bourboulis, In 
vitro activity of rifaximin against isolates from patients with small intestinal bacterial 
overgrowth, International journal of antimicrobial agents, 43 (2014) 236-241. 
[26] X. Corbella, M. Pujol, J. Ayats, M. Sendra, C. Ardanuy, M.A. Dominguez, J. Linares, J. 
Ariza, F. Gudiol, Relevance of digestive tract colonization in the epidemiology of nosocomial 
infections due to multiresistant Acinetobacter baumannii, Clinical infectious diseases : an 
official publication of the Infectious Diseases Society of America, 23 (1996) 329-334. 
[27] J.A. Winkelstein, M.C. Marino, H.M. Lederman, S.M. Jones, K. Sullivan, A.W. Burks, M.E. 
Conley, C. Cunningham-Rundles, H.D. Ochs, X-linked agammaglobulinemia: report on a 
United States registry of 201 patients, Medicine, 85 (2006) 193-202. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
[28] E.W. Herbst, M. Armbruster, J.A. Rump, H.P. Buscher, H.H. Peter, Intestinal B cell 
defects in common variable immunodeficiency, Clinical and experimental immunology, 95 
(1994) 215-221. 
[29] A.A. van de Ven, W.J. Janssen, L.S. Schulz, A.M. van Loon, K. Voorkamp, E.A. Sanders, J.G. 
Kusters, S. Nierkens, M. Boes, A.M. Wensing, J.M. van Montfrans, Increased prevalence of 
gastrointestinal viruses and diminished secretory immunoglobulin a levels in antibody 
deficiencies, Journal of clinical immunology, 34 (2014) 962-970. 
[30] T. Klemola, Immunohistochemical findings in the intestine of IgA-deficient persons: 
number of intraepithelial T lymphocytes is increased, Journal of pediatric gastroenterology 
and nutrition, 7 (1988) 537-543. 
[31] J. Fadlallah, H. El Kafsi, D. Sterlin, C. Juste, C. Parizot, K. Dorgham, G. Autaa, D. Gouas, M. 
Almeida, P. Lepage, N. Pons, E. Le Chatelier, F. Levenez, S. Kennedy, N. Galleron, J.P. de 
Barros, M. Malphettes, L. Galicier, D. Boutboul, A. Mathian, M. Miyara, E. Oksenhendler, Z. 
Amoura, J. Dore, C. Fieschi, S.D. Ehrlich, M. Larsen, G. Gorochov, Microbial ecology 
perturbation in human IgA deficiency, Science translational medicine, 10 (2018). 
[32] M. Vlkova, O. Ticha, J. Nechvatalova, T. Kalina, J. Litzman, C. Mauri, P.A. Blair, 
Regulatory B cells in CVID patients fail to suppress multifunctional IFN-gamma+ TNF-
alpha+ CD4+ T cells differentiation, Clinical immunology, 160 (2015) 292-300. 
[33] S.F. Jorgensen, H.M. Reims, D. Frydenlund, K. Holm, V. Paulsen, A.E. Michelsen, K.K. 
Jorgensen, L.T. Osnes, J. Bratlie, T.J. Eide, C.P. Dahl, E. Holter, R.R. Tronstad, K. Hanevik, H.R. 
Brattbakk, F. Kaveh, T. Fiskerstrand, A.B. Kran, T. Ueland, T.H. Karlsen, P. Aukrust, K.E. 
Lundin, B. Fevang, A Cross-Sectional Study of the Prevalence of Gastrointestinal Symptoms 
and Pathology in Patients With Common Variable Immunodeficiency, The American journal 
of gastroenterology, 111 (2016) 1467-1475. 
[34] J.M. Woodward, E. Gkrania-Klotsas, A.Y. Cordero-Ng, A. Aravinthan, B.N. Bandoh, H. 
Liu, S. Davies, H. Zhang, P. Stevenson, M.D. Curran, D. Kumararatne, The role of chronic 
norovirus infection in the enteropathy associated with common variable 
immunodeficiency, The American journal of gastroenterology, 110 (2015) 320-327. 
[35] S.M. Karst, C.E. Wobus, A working model of how noroviruses infect the intestine, PLoS 
pathogens, 11 (2015) e1004626. 
[36] A. Hakansson, G. Molin, Gut microbiota and inflammation, Nutrients, 3 (2011) 637-
682. 
[37] C.M. Chiu, W.C. Huang, S.L. Weng, H.C. Tseng, C. Liang, W.C. Wang, T. Yang, T.L. Yang, 
C.T. Weng, T.H. Chang, H.D. Huang, Systematic analysis of the association between gut flora 
and obesity through high-throughput sequencing and bioinformatics approaches, BioMed 
research international, 2014 (2014) 906168. 
[38] P.J. Sebeny, M.S. Riddle, K. Petersen, Acinetobacter baumannii skin and soft-tissue 
infection associated with war trauma, Clinical infectious diseases : an official publication of 
the Infectious Diseases Society of America, 47 (2008) 444-449. 
[39] K.A. Davis, K.A. Moran, C.K. McAllister, P.J. Gray, Multidrug-resistant Acinetobacter 
extremity infections in soldiers, Emerging infectious diseases, 11 (2005) 1218 -1224. 
[40] L.L. Maragakis, T.M. Perl, Acinetobacter baumannii: epidemiology, antimicrobial 
resistance, and treatment options, Clinical infectious diseases : an official publication of the 
Infectious Diseases Society of America, 46 (2008) 1254-1263. 
[41] J. Garnacho-Montero, C. Ortiz-Leyba, E. Fernandez-Hinojosa, T. Aldabo-Pallas, A. 
Cayuela, J.A. Marquez-Vacaro, A. Garcia-Curiel, F.J. Jimenez-Jimenez, Acinetobacter 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
baumannii ventilator-associated pneumonia: epidemiological and clinical findings, 
Intensive care medicine, 31 (2005) 649-655. 
[42] L.S. Young, A.L. Sabel, C.S. Price, Epidemiologic, clinical, and economic evaluation of an 
outbreak of clonal multidrug-resistant Acinetobacter baumannii infection in a surgical 
intensive care unit, Infection control and hospital epidemiology, 28 (2007) 1247-1254. 
[43] M.S. Tang, R. Bowcutt, J.M. Leung, M.J. Wolff, U.M. Gundra, D. Hudesman, L.B. Malter, 
M.A. Poles, L.A. Chen, Z. Pei, A.G. Neto, W.M. Abidi, T. Ullman, L. Mayer, R.A. Bonneau, I. Cho, 
P. Loke, Integrated Analysis of Biopsies from Inflammatory Bowel Disease Patients 
Identifies SAA1 as a Link Between Mucosal Microbes with TH17 and TH22 Cells, Inflamm 
Bowel Dis, 23 (2017) 1544-1554. 
[44] C.R. Petersen JA, Specificity of the Adaptive Immune Response to the Gut Microbiota, 
in: C.A. Fagarasan A (Ed.) In Advances in Immunology, Mucosal Immunity., vol. 107, 
Academic Press 2010. 
[45] J. Park, I. Munagala, H. Xu, D. Blankenship, P. Maffucci, D. Chaussabel, J. Banchereau, V. 
Pascual, C. Cunningham-Rundles, Interferon signature in the blood in inflammatory 
common variable immune deficiency, PloS one, 8 (2013) e74893. 
[46] J. Schindelin, I. Arganda-Carreras, E. Frise, V. Kaynig, M. Longair, T. Pietzsch, S. 
Preibisch, C. Rueden, S. Saalfeld, B. Schmid, J.Y. Tinevez, D.J. White, V. Hartenstein, K. 
Eliceiri, P. Tomancak, A. Cardona, Fiji: an open-source platform for biological-image 
analysis, Nature methods, 9 (2012) 676-682. 
[47] W. Huang da, B.T. Sherman, R.A. Lempicki, Systematic and integrative analysis of large 
gene lists using DAVID bioinformatics resources, Nature protocols, 4 (2009) 44-57. 
[48] A. Subramanian, P. Tamayo, V.K. Mootha, S. Mukherjee, B.L. Ebert, M.A. Gillette, A. 
Paulovich, S.L. Pomeroy, T.R. Golub, E.S. Lander, J.P. Mesirov, Gene set enrichment analysis: 
a knowledge-based approach for interpreting genome-wide expression profiles, 
Proceedings of the National Academy of Sciences of the United States of America, 102 
(2005) 15545-15550. 
[49] K.L. Mine, N. Shulzhenko, A. Yambartsev, M. Rochman, G.F. Sanson, M. Lando, S. Varma, 
J. Skinner, N. Volfovsky, T. Deng, S.M. Brenna, C.R. Carvalho, J.C. Ribalta, M. Bustin, P. 
Matzinger, I.D. Silva, H. Lyng, M. Gerbase-DeLima, A. Morgun, Gene network reconstruction 
reveals cell cycle and antiviral genes as major drivers of cervical cancer, Nature 
communications, 4 (2013) 1806. 
[50] N. Shulzhenko, A. Yambartsev, A. Goncalves-Primo, M. Gerbase-DeLima, A. Morgun, 
Selection of control genes for quantitative RT-PCR based on microarray data, Biochemical 
and biophysical research communications, 337 (2005) 306-312. 
[51] T. Farkas, W.M. Zhong, Y. Jing, P.W. Huang, S.M. Espinosa, N. Martinez, A.L. Morrow, 
G.M. Ruiz-Palacios, L.K. Pickering, X. Jiang, Genetic diversity among sapoviruses, Archives of 
virology, 149 (2004) 1309-1323. 
 
Figure 1. Gene expression and cellular characterization of CVID enteropathy. 
(a) Number of genes assigned to each of the three signatures (E-CVID, noE-CVID and 
all-CVID) defined as described in Methods and Supplementary Figure 1. (b) heatmap of 
genes in E-CVID profile; columns, samples (Control n=7, noE-CVID n=8, E-CVID n=7), 
rows, genes; log2 normalized intensities of gene expression across all samples are 
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represented. (c) Enriched Gene Ontology terms (Biological Process) in E-CVID profile 
(p-values obtained using DAVID bioinformatics resources). (d) Gene set enrichment 
analysis (GSEA) for hematopoietic cell types in E-CVID vs. other groups; *p<0.05; # 
p<0.1 by permutation test implemented in GSEA. (e) GSEA leading edge scores and 
genes for CD8 effector/memory cells and M1 macrophages. Leading edge plots for 
other enriched populations are in Supplementary Figure S2. (f) Representative images 
and quantitative analysis of CD8 staining in biopsies from Control  (n=4), noE-CVID 
(n=6), E-CVID (n=7), Mann-Whitney one-sided test *p<0.05; #p<0.1, mean, SEM 
shown. Abbreviations: E-CVID, enteropathy associated with common variable 
immunodeficiency; noE-CVID, CVID without enteropathy; Ctrl, Control; Bas, basophils, 
Eos, eosinophils; Neutr, neutrophils; Mono, monocytes; DCs, dendritic cells; NK, natural 
killer cells. 
Figure 2. Intestinal IgA levels discriminate patients with and without CVID enteropathy. 
(a) Levels of total IgA in serum of CVID patients. (b) Expression of genes coding for 
IgA1, IgA2, IgM, IgG1, IgG2, IgG3, IgG4 in duodenal biopsies of CVID patients with 
enteropathy (n=6), noE-CVID (n=8) and Control subjects (n=7); *p<0.05; # p<0.1, one-
sided t-test, comparing E-CVID to other groups, mean/SD shown. (c) Representative 
images of IgA immunohistochemistry in duodenal biopsies and quantitative analysis, 
*p<0.05; # p<0.1 Mann-Whitney one-sided test comparing E-CVID to other groups; cpm 
stands for counts per million. 
 
Figure 3. Microbiome analysis of duodenal biopsies.  
 (a) Tree-of-life plot at the genus level; bars represent relative frequencies; red, E-CVID, 
blue, noE-CVID, green, Control; Acinetobacter genus is indicated by dashed box as it 
will be focus of the analysis in Fig 4. (b) Principal coordinate analysis of microbiota 
composition in biopsies. (c) Shannon index estimating microbiome diversity in groups of 
samples; blue dot is an outlier sample, no significant differences detected between 
groups by one-sided t test. (d) Correlations between OTU abundances and levels of 
IGHA1 (left) or IGHA2 (right) mRNA plotted against change in OTU Frequency in E-
CVID vs. all other samples. OTU, operational taxonomic unit. Red color indicates OTUs 
that pass FDR 0.2 with stronger intensity corresponding to lower FDR. OTUs marked in 
grey present FDR above 0.2. E-CVID, enteropathy associated with common variable 
immunodeficiency; noE-CVID, CVID without enteropathy; Ctrl, Control subjects. 
 
Figure 4. Transkingdom network analysis identifies Acinetobacter baumannii as a 
candidate microbe driving CVID enteropathy.  
(a) Transkingdom network reconstructed from levels of expression of human genes 
from E-CVID signature and candidate microbes selected based on analysis in Fig. 3d; 
orange and blue indicate upregulated and downregulated genes in E-CVID, 
respectively; green and yellow are bacterial OTUs increased or decreased in E-CVID, 
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respectively. (b) Number of connections to genes upregulated in E-CVID and average 
abundance in E-CVID biopsies are plotted for each OTU identified by analysis in Fig. 
3d. (c) Number of reads corresponding to species of Acinetobacter genus in biopsies 
based on shotgun metagenomics. (d) Number of biopsy samples positive or negative for 
Acinetobacter in each patient group (p<0.04, Chi-square test). (e) Gene expression from 
E-CVID signature as assessed by RNAseq in THP-1 cells after 6 h of incubation with A. 
baumannii. Representative genes are indicated and levels of expression of the same 
genes in biopsies with E-CVID or noE-CVID are shown; full list of genes is in 
Supplementary Table S13.  
 
Figure 5. Interferons Drive Inhibition of Lipid Metabolism in Epithelial Cells. 
(a) Expression of IFNB1 and IFN type I dependent genes (RSAD2, OAS2, MX1) in 
duodenal biopsies from of CVID patients with (red), without (blue) enteropathy and 
control subjects (green), all genes passed false discovery rate <0.03 comparing E-CVID 
to other two groups. (b) expression of IFNG and IFN type II dependent genes (GBP1, 
IDO, TAP1); (c) Gene expression ratios between E-CVID and control individuals (y axis) 
and between interferon treated versus untreated human epithelial cells (x axis; n=3 per 
group), left panel both types of interferons; middle panel interferon type I; right panel 
interferon type II. (d) Expression of genes defined as lipid metabolism by Gene 
Ontology and downregulated in E-CVID, representative genes are indicated; left panel: 
median values in E-CVID and noE-CVID tissues; right panel: individual values in cells 
treated and untreated with both interferons, red is high and blue is low expression; (e) 
intracellular cholesterol levels in epithelial cells treated or untreated with both types of 
interferons  data presented as mean±s.e.m.; each column number of biological 
replicates equals 14 (**p<0.0001 by one-tailed Wilcoxon test); (f) model of CVID 
enteropathy.  
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